KRAS and cancer: Acute myeloid leukemia, glioma, triple-negative breast cancer, K-Ras mutant lung cancer, and hepatitis B-induced HCC exhibit high rates of FAO (54–58) while some non-glycolytic cancers such as prostate tumor and diffuse large B-cell lymphoma, preferentially use FAO as the dominant bioenergetic pathway for survival (3, 59).